Mokari Atabak sold $9.2M of CORT

Mokari Atabak (Chief Financial Officer) sold 80,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.71 ($105.54–$120.67, $9.18M total) across 13 trades on 2026-07-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mokari Atabak
Published Aug 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosure updates the insider trading record and may influence short-term sentiment, but it does not provide new company fundamentals.

02

Market read

A CFO open-market sale of roughly $9.18M in CORT shares under a 10b5-1 plan is disclosed, with likely limited trading impact absent other catalysts.

03

What to watch

The filing does not disclose whether other insiders or the company announced offsetting catalysts (buybacks, guidance, trial updates), so traders should not infer fundamental deterioration from this alone.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-03, transaction dated 2026-07-30

Background

The article is an SEC Form 4 insider transaction report for Corcept Therapeutics, filed by the CFO.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics CFO Mokari Atabak sold about $9.18M of CORT shares via an open-market sale under a 10b5-1 plan on 2026-07-30.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no accompanying company-specific news (earnings, guidance, deals, or regulatory actions).

Market effects

Minimal. Insider sales under 10b5-1 typically do not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the transaction may reflect liquidity planning rather than bearish expectations, so any price reaction may be overdone.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure.

  • Mokari Atabak

    Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.